Anti-CD19 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Intrexon/ZIOPHARM

Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - ZIOPHARM/Intrexon; CD19RCD28

Latest Information Update: 17 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Developer Intrexon Corporation; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center; ZIOPHARM Oncology
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I B cell lymphoma; Leukaemia
  • Preclinical Multiple myeloma

Most Recent Events

  • 10 May 2018 MD Anderson Cancer Center submits an IND application to the US FDA for a point-of-care phase I trial in CD19+ leukaemia and lymphoma
  • 10 Dec 2017 ZIOPHARM Oncology plans a phase I point-of-care clinical trial in CD19+ leukaemia and lymphoma in second half of 2018
  • 10 Dec 2017 Interim efficacy and adverse events data from an ongoing phase I trial in B-cell lymphoma and Leukaemia released by ZIOPHARM Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top